Company Overview

ProUroCare Medical Inc. (OTC: PUMD) was a medical technology company focused on the detection and management of prostate disease, particularly prostate cancer. The company operated within the urology and diagnostic medical device industries and was primarily known for developing technologies intended to improve prostate examination accuracy and support earlier clinical detection. Public filings and historical investor materials identify the company’s principal commercial focus as the development and commercialization of its prostate diagnostic platform.

The company’s primary product platform was the ProUroScan system, a computer-assisted diagnostic device designed to enhance the traditional digital rectal examination through pressure-sensing technology and imaging analytics. ProUroCare positioned its technology as a non-invasive adjunct tool for physicians treating patients with elevated prostate cancer risk or abnormal screening results. Historically, the company evolved from an early-stage medical device developer into a commercialization-focused organization seeking regulatory adoption and broader physician utilization. Data regarding recent operating scale and commercialization progress is inconclusive based on available public sources.

Business Operations

ProUroCare’s operations centered on the development, regulatory support, and commercialization of its prostate diagnostic technology. The company historically generated limited revenue through device sales, licensing activity, and related clinical evaluation efforts tied to the ProUroScan platform. Public disclosures indicate that the company concentrated heavily on research, product validation, intellectual property development, and physician adoption initiatives rather than diversified recurring commercial revenue streams.

Operationally, the company’s activities were primarily based in the United States, with emphasis on the urology care market and clinical partnerships supporting product evaluation. Its principal controlled asset was the proprietary pressure-based prostate examination technology embedded within the ProUroScan system and related patents. Available public records do not indicate the existence of large-scale international subsidiaries or major joint ventures comparable to larger medical device companies. Information regarding current active partnerships or ongoing commercial distribution arrangements remains limited in publicly accessible filings.

Strategic Position & Investments

ProUroCare’s strategic direction focused on establishing differentiated prostate diagnostic tools within a healthcare market increasingly emphasizing earlier cancer detection and minimally invasive screening methods. The company sought to position the ProUroScan system as a supplemental clinical tool that could improve physician decision-making alongside conventional prostate-specific antigen (PSA) testing and standard physical examination methods. Its growth initiatives historically included physician outreach, clinical validation studies, intellectual property protection, and attempts to expand reimbursement and market acceptance.

The company also pursued investment in proprietary software, sensor technologies, and data-driven diagnostic capabilities connected to prostate imaging and examination analytics. Publicly available filings and historical disclosures do not show evidence of large acquisitions or a broad portfolio of operating subsidiaries. Data regarding more recent strategic investments, financing activity, or active commercialization programs is inconclusive based on available public sources.

Geographic Footprint

ProUroCare Medical Inc. primarily operated in the United States, where its headquarters and principal commercialization activities were historically located. The company targeted domestic urology practices, healthcare providers, and clinical institutions involved in prostate cancer screening and diagnosis. Its regulatory and operational focus appeared centered on the U.S. medical device market and associated FDA-related commercialization pathways.

Although the company’s technology had potential relevance for broader international healthcare markets, publicly available information indicates limited direct global operational infrastructure. There is insufficient verified evidence of substantial operational presence across Europe, Asia-Pacific, or other major international regions. Data regarding current international distribution relationships or overseas clinical programs is inconclusive based on available public sources.

Leadership & Governance

ProUroCare’s leadership historically consisted of executives with backgrounds in medical devices, diagnostics, commercialization, and healthcare operations. Public filings indicate that management strategy emphasized clinical validation, regulatory compliance, and physician adoption as central drivers of long-term value creation. As with many developmental-stage medical technology companies, leadership focus appeared directed toward capital access, commercialization execution, and intellectual property development.

Key executives identified in historical public filings include:

• J. Todd Wilkinson – Chief Executive Officer
• Richard Ferrari – Chairman
• Andrew J. Killion – Chief Financial Officer

Information regarding current executive leadership, board composition, and governance structure is limited in recent publicly available disclosures. Data inconclusive based on available public sources.